US 12,465,596 B2
Stabilisation and controlled-release systems for medicaments unstable on sterilisation
Cristian Guarise, Abano Terme (IT); and Carlo Pizzocaro, Abano Terme (IT)
Assigned to FIDIA FARMACEUTICI S.p.A., Abano Terme (IT)
Appl. No. 17/440,396
Filed by FIDIA FARMACEUTICI S.P.A., Abano Terme (IT)
PCT Filed Jan. 28, 2020, PCT No. PCT/IB2020/050636
§ 371(c)(1), (2) Date Sep. 17, 2021,
PCT Pub. No. WO2020/188365, PCT Pub. Date Sep. 24, 2020.
Claims priority of application No. 102019000003887 (IT), filed on Mar. 18, 2019.
Prior Publication US 2022/0241251 A1, Aug. 4, 2022
Int. Cl. A61K 31/436 (2006.01); A61K 9/107 (2006.01); A61K 31/202 (2006.01); A61K 31/22 (2006.01); A61K 31/337 (2006.01); A61K 31/495 (2006.01); A61K 31/573 (2006.01); A61K 38/23 (2006.01); A61K 47/18 (2017.01); A61K 47/36 (2006.01); A61P 19/02 (2006.01)
CPC A61K 31/436 (2013.01) [A61K 9/1075 (2013.01); A61K 31/202 (2013.01); A61K 31/22 (2013.01); A61K 31/337 (2013.01); A61K 31/495 (2013.01); A61K 31/573 (2013.01); A61K 38/23 (2013.01); A61K 47/18 (2013.01); A61K 47/36 (2013.01); A61P 19/02 (2018.01)] 13 Claims
 
1. Sulfated hyaluronic acid amides (HAS) with C4-C20 alkenylamines, wherein a molar degree of derivatization of the alkenylamine in the sulfated hyaluronic acid amide ranges from 2 to 20%.